Business Context and Reporting Period
This Form 8-K filing by Lyell Immunopharma, Inc. (LYEL) was submitted on January 24, 2025, reporting an event that occurred on January 23, 2025. The filing addresses a regulatory notice regarding the company's continued listing status on The Nasdaq Global Select Market.
Key Financial Metrics
The filing does not provide specific financial data such as revenue, profit, cash flow, margins, debt, or liquidity. The only quantitative metric disclosed is the stock price performance triggering the regulatory notice: the closing bid price of the Company's common stock remained below $1.00 per share for 33 consecutive business days.
Material Changes
The material change reported is the receipt of a formal notice from Nasdaq indicating a failure to satisfy the minimum closing bid price requirement under Listing Rule 5450(a)(1). This deficiency has persisted for 33 consecutive business days. The notice has no immediate effect on the listing but initiates a compliance timeline.
Outlook, Risks, and Management Commentary
- Compliance Timeline: The Company has 180 calendar days, until July 22, 2025, to regain compliance. To do so, the stock must close at or above $1.00 per share for 10 consecutive business days prior to the deadline.
- Contingency Plans: If compliance is not achieved by the deadline, the Company may be eligible for an additional 180-day period, contingent upon transferring its listing to The Nasdaq Capital Market and meeting other initial listing standards (excluding the bid price requirement).
- Management Action: Management intends to actively monitor the stock price and evaluate potential actions, including effecting a reverse stock split, if necessary.
- Risks: There is no assurance that the Company will regain compliance or that an appeal against a potential delisting determination would be successful. Failure to comply could result in delisting.
Investor Verification Checklist
- Verify the current closing bid price of LYEL stock to assess proximity to the $1.00 threshold.
- Monitor upcoming shareholder meetings or board announcements regarding the potential implementation of a reverse stock split.
- Review the Company's most recent Form 10-K and 10-Q filings for details on cash reserves and burn rate, as these impact the ability to sustain operations during a potential delisting or restructuring period.
- Track the July 22, 2025 compliance deadline and any subsequent communications from Nasdaq regarding the Company's status.